Graves' disease: A long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery

Thyroid

Volumn 15, Issue 11, 2005, Pages 1279-1286

  Abraham Nordling, Mirna ^a   Törring, Ove ^b   Hamberger, Bertil ^a   Lundell, Göran ^a   Tallstedt, Leif ^c   Calissendorff, Jan ^a   Wallin, Göran ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; IODINE 131; LIOTHYRONINE; RADIOACTIVE IODINE; THYROTROPIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EMOTION; FEMALE; FOLLOW UP; GRAVES DISEASE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SWEDEN; THYROID FUNCTION; THYROID SURGERY;

ADULT; AGING; ANTITHYROID AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HEALTH; HUMANS; IODINE RADIOISOTOPES; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; SOCIAL BEHAVIOR; SWEDEN; THYROIDECTOMY; THYROTROPIN;

EID: 29244465086     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.1279     Document Type: Article

References (31)

1. Berglund J, Ericsson UB, Hallengren B 1996 Increased incidence of thyrotoxicosis in Malmo during the years 1988-1990 as compared to the years 1970-1974. J Intern Med 239:57-62.
2. Furszyfer J, Kurland LT, McConahey WM, Elveback LR 1970 Graves' disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc 45:636-644.
3. Galofre JC, Garcia-Mayor RV, Fluiters E, Fernandez-Calvet L, Rego A, Paramo C, Andrade MA 1994 Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area. Thyroidology 6:49-54.
4. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, et al. 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43:55-68.
5. Mostbeck A, Galvan G, Bauer P, Eber O, Atefie K, Dam K, Feichtinger H, Fritzsche H, Haydl H, Kohn H, Konig B, Koriska K, Kroiss A, Lind P, Markt B, Maschek W, Pesl H, Ramschak-Schwarzer S, Riccabona G, Stockhammer M, Zechmann W 1998 The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J Nucl Med 25:367-374.
6. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1:129-135.
7. Ford HC, Delahunt JW, Feek CM 1991 The management of Graves' disease in New Zealand: results of a national survey. N Z Med J 104:251-252.
8. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 326:1733-1738.
9. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B 1996 Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodint-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 81:2986-2993.
10. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G 1998 Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8:653-659.
11. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM 1997 Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7:885-889.
12. Egle UT, Kahaly GJ, Petrak F, Hardt J, Batke J, Best J, Rothenbacher M 1999 The relevance of physical and psychosocial factors for the quality of life in patients with thyroid-associated orbitopathy (GO). Exp Clin Endocrinol Diabetes 107(Suppl 5):S168-S171.
13. Kahaly GJ, Hardt J, Petrak F, Egle UT 2002 Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 12:237-239.
14. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W 2002 Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol 146:751-757.
15. Kathol RG, Turner R, Delahunt J 1986 Depression and anxiety associated with hyperthyroidism: response to antithyroid therapy. Psychosomatics 27:501-505.
16. Trzepacz PT, McCue M, Klein I, Greenhouse J, Levey GS 1988 Psychiatric and neuropsychological response to propranolol in Graves' disease. Biol Psychiatry 23:678-688.
17. Paschke R, Harsch I, Schlote B, Vardarli I, Schaaf L, Kaumeier S, Teuber J, Usadel KH 1990 Sequential psychological testing during the course of autoimmune hyperthyroidism. Klin Wochenschr 68:942-950.
18. Perrild H, Hansen JM, Arnung K, Olsen PZ, Danielsen U 1986 Intellectual impairment after hyperthyroidism. Acta Endocrinol (Copenh). 112:185-191.
19. Bommer M, Eversmann T, Pickardt R, Leonhardt A, Naber D 1990 Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr 68:552-558.
20. Fahrenfort JJ, Wilterdink AM, van der Veen EA 2000 Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 25:201-211.
21. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H, Waldemar G 2004 Impaired health-related quality of life in Graves' disease. A prospective study. Eur J Endocrinol 151:549-555.
22. Sullivan M, Karlsson J, Ware JE Jr 1995 The Swedish SF-36 Health Survey-I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 41:1349-1358.
23. Persson LO, Karlsson J, Bengtsson C, Steen B, Sullivan M 1998 The Swedish SF-36 Health Survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. J Clin Epidemiol 51:1095-1103.
24. Sullivan M, Karlsson J 1998 The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol 51:1105-1113.
25. Ware JE Jr, Sherbourne CD 1992 The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483.
26. Gorman CA 1983 Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 58:515-519.
27. Wiersinga WM, Smit T, van der Gaag R, Koornneef L 1998 Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. J Endocrinol Invest 11:615-619.
28. JJ Park, TJ Sullivan, RH Mortimer, M Wagenaar, and DA Perry-Keene 2004 Assessing quality of life in Australian patients with Graves' ophthalmopathy Br J Ophthalmol 88:75-78.
29. Dittmar M, Kahaly GJ 2003 Extensive personal experience. Polyglandular autoimmune syndromes: Immunogenetics and long-term follow-up. J Clin Endocrinol Metab 88:2983-2992.
30. Eisenbarth GS, Gottlieb PA 2004 Autoimmune Polyendocrine Syndromes. N Engl J Med 350:2068-2079.
31. Ten S, New M, MacLaren N 2001 Clinical review 130: Addison's disease. J Clin Endocrinol Metab 86:2909-2922.